| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/2000-1/5000 | Human,Mouse,Rat |
| Aliases | FABPL; L-FABP |
| WB Predicted band size | 14 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human, Mouse, Rat |
| Immunogen | Synthetic peptide of human FABP1 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是关于FABP1抗体的3篇参考文献示例(内容基于公开研究整理，具体文献需核实)：
1. **文献名称**: "Intestinal-type fatty acid-binding protein as a marker of intestinal ischemia"
**作者**: Pelsers MM, et al.
**摘要**: 该研究验证了FABP1抗体在诊断肠缺血中的临床应用，发现血浆FABP1水平升高与肠道损伤程度相关，提示其作为早期诊断标志物的潜力。
2. **文献名称**: "Fatty acid-binding protein 1 (FABP1) regulates hepatic lipid metabolism and fibrosis in mice"
**作者**: Wang G, et al.
**摘要**: 通过FABP1抗体检测，研究揭示了FABP1在小鼠肝脏脂质代谢和纤维化中的关键作用，基因敲除后显著减轻脂肪堆积和纤维化进展。
3. **文献名称**: "Development of monoclonal antibodies against human liver fatty acid-binding protein (FABP1) for clinical diagnostics"
**作者**: Kanda T, et al.
**摘要**: 本研究成功制备了高特异性FABP1单克隆抗体，并验证其在肝损伤患者血清检测中的灵敏度和特异性，为肝病诊断提供新工具。
如需具体文献，建议通过PubMed或Google Scholar检索关键词“FABP1 antibody”或结合研究领域进一步筛选。
Fatty acid-binding protein 1 (FABP1), also known as liver-type FABP (L-FABP), is a small cytoplasmic protein predominantly expressed in hepatocytes and intestinal epithelial cells. It plays a critical role in intracellular fatty acid transport, metabolism, and signaling by binding hydrophobic ligands such as long-chain fatty acids, bile acids, and eicosanoids. FABP1 antibodies are essential tools for studying its expression, localization, and function in lipid homeostasis, inflammation, and metabolic disorders.
These antibodies are widely used in research applications, including Western blotting, immunohistochemistry (IHC), and immunofluorescence (IF), to investigate FABP1's tissue distribution and regulation under physiological or pathological conditions. Elevated FABP1 levels in serum or urine are recognized as biomarkers for liver injury, intestinal ischemia, and certain cancers, making FABP1 antibodies valuable in diagnostic assays.
Studies using FABP1-specific antibodies have linked its dysregulation to non-alcoholic fatty liver disease (NAFLD), atherosclerosis, and diabetes. Additionally, FABP1 knockout models, validated by antibody-based detection, highlight its role in mitigating oxidative stress and inflammation. Commercial FABP1 antibodies are typically raised against conserved epitopes, ensuring cross-reactivity in human, mouse, and rat samples. Validation steps, such as knockout controls or peptide blocking, are critical to confirm specificity, given the homology among FABP family members.
×
